临床上常常遇到患者合并多种疾病而需要进行药物联合治疗。此时，若是不了解这些药物之间的相互作用并及时调整用法用量，有可能会造成严重的后果。接下来，用 4 张表格跟大家介绍内分泌科常用药与其他药物相互作用机制以及临床处理意见。快来收藏吧～
1. 降糖药
2. 左甲状腺素钠
3. 糖皮质激素
4. 其他常用药
推荐阅读：
编辑 | 玥廷
投稿 | dongyt@dxy.cn
题图 | shutterstock.com
参考文献： [1]YANG W,LU J,WENG J, et al. Prevalence of diabetes among men and women in China[J].NEng J Med,2010,362:1090-1101. [2] Horn JR, Gumpper KF, Hardy JC, et al.Clinical decision support for drug-drug interactions: Improvement needed [J].Am J Health Syst Pharm, 2013, 70(10): 905-909 [3]菅凌燕,何晓静,李晓冰. 与α-糖苷酶抑制剂治疗相关的药物相互作用[J]. 药品评价,2015,12(17):21-24. [4] May M,Schindler C.Clinically and pharmacologically relevant interactions of antidiabeticdrugs.Ther Adv Endocrinol Metab. 2016 ,7(2):69-83. [5]Irving SA1, Vadiveloo T, Leese GP. Drugs thatinteract with levothyroxine: an observational study from the ThyroidEpidemiology, Audit and Research Study (TEARS).Clin Endocrinol (Oxf). 2015,82(1):136-141 [6]Rizzoli R1, Reginster JY, Boonen S, etal.Adverse reactions and drug-drug interactions in the management of women withpostmenopausal osteoporosis. Calcif Tissue Int. 2011,89(2):91-104. [7]Kusumoto M, Ueno K, Fujimura Y, et al. Lack ofkinetic interaction between digoxin and voglibose.Eur J Clin Pharmacol. 1999 ,55(1):79-80. [8]Tahboub R, Arafah BM. Sex steroids and thethyroid .Best Pract Res Clin Endocrinol Metab. 2009 ,23(6):769-780. [9]李中东,施孝金,王宏图.左甲状腺素钠的药物相互作用及机制初探.药学服务与研究 2003, 3(1):59-61 [10]Yang R, Luo Z, Liu Y1, Sun M.DrugInteractions with Angiotensin Receptor Blockers: Role of Human CytochromesP450.Curr Drug Metab. 2016;17(7):681-691. [11]Tornio A, Niemi M, Neuvonen PJ, Druginteractions with oral antidiabetic agents: pharmacokinetic mechanisms andclinical implications.Trends Pharmacol Sci. 2012 ,33(6):312-322. [12]Scheen A J. Dipeptidylpeptidase-4 inhibitors(gliptins): focus on drug-drug interactions. Clin Pharmacokinet. 2010,49(9):573-588 [13]Hurren KM1, Pinelli NR. Drug-druginteractions with glucagon-like peptide-1 receptor agonists. Ann Pharmacother.2012,46(5):710-717. [14]母义明. 2型糖尿病治疗中的药物相互作用[J]. 药品评价,2015,12(17):8-14 [15] Zhou YT, YuLS, ZengS, et al.Pharmacokinetic drug-drug interactions between 1.4-dihydropyridine calciumchannel blockers and statins: factors determining interaction strength andrelevant clinical risk management. Ther Clin Risk Manag. 2014;10:17-26. [16]Wiggins BS, Saseen JJ, Page RL2nd,Recommendations for Management of Clinically Significant Drug-DrugInteractions With Statins and Select Agents Used in Patients WithCardiovascular Disease: A Scientific Statement From the American Heart Association.Circulation.2016, 22;134(21):468-495. [17]徐海燕,刘冬,王文刚,孔令提. 他汀类药物与常见心血管药物相互作用的研究进展[J]. 中国药房,2016,27(11):1582-1584. [18]Matoulková P1, Pávek P, Malý J, et al. Cytochrome P450 enzymeregulation by glucocorticoids and consequences in terms of drug interaction.Expert Opin Drug Metab Toxicol. 2014 ,10(3):425-35. [19]Stage TB, Brøsen K, Christensen MM, et al.A Comprehensive Review of Drug-Drug Interactions withMetformin. Clin Pharmacokinet (2015) 54:811–824 [20]Koepsell H. Role of organic cation transportersin drug-drug interaction. Expert Opin Drug Metab Toxicol. 2015;11(10):1619-1633. [21]Johansson S, Read J, Oliver S.Pharmacokineticevaluations of the co-administrations of vandetanib and metformin, digoxin,midazolam, omeprazole or ranitidine.Clin Pharmacokinet. 2014 ,53(9):837-47. [22]Rehman SU, Choi MS, Choe K, et al. Interactionsbetween herbs and antidiabetics: an overview of the mechanisms, evidence,importance, and management. Arch Pharm Res. 2015 ,38(7):1281-98.
联系客服
